Therapeutic Drug Monitoring of Antibiotic Drugs in Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis: A Critical Review.
Journal
Therapeutic drug monitoring
ISSN: 1536-3694
Titre abrégé: Ther Drug Monit
Pays: United States
ID NLM: 7909660
Informations de publication
Date de publication:
01 02 2022
01 02 2022
Historique:
received:
31
07
2021
accepted:
16
09
2021
pubmed:
14
11
2021
medline:
24
3
2022
entrez:
13
11
2021
Statut:
ppublish
Résumé
Antibiotics are frequently used in patients receiving intermittent or continuous renal replacement therapy (RRT). Continuous renal replacement may alter the pharmacokinetics (PK) and the ability to achieve PK/pharmacodynamic (PD) targets. Therapeutic drug monitoring (TDM) could help evaluate drug exposure and guide antibiotic dosage adjustment. The present review describes recent TDM data on antibiotic exposure and PK/PD target attainment (TA) in patients receiving intermittent or continuous RRT, proposing practical guidelines for performing TDM. Studies on antibiotic TDM performed in patients receiving intermittent or continuous RRT published between 2000 and 2020 were searched and assessed. The authors focused on studies that reported data on PK/PD TA. TDM recommendations were based on clinically relevant PK/PD relationships and previously published guidelines. In total, 2383 reports were retrieved. After excluding nonrelevant publications, 139 articles were selected. Overall, 107 studies reported PK/PD TA for 24 agents. Data were available for various intermittent and continuous RRT techniques. The study design, TDM practice, and definition of PK/PD targets were inconsistent across studies. Drug exposure and TA rates were highly variable. TDM seems to be necessary to control drug exposure in patients receiving intermittent and continuous RRT techniques, especially for antibiotics with narrow therapeutic margins and in critically ill patients. Practical recommendations can provide insights on relevant PK/PD targets, sampling, and timing of TDM for various antibiotic classes. Highly variable antibiotic exposure and TA have been reported in patients receiving intermittent or continuous RRT. TDM for aminoglycosides, beta-lactams, glycopeptides, linezolid, and colistin is recommended in patients receiving RRT and suggested for daptomycin, fluoroquinolones, and tigecycline in critically ill patients on RRT.
Identifiants
pubmed: 34772891
doi: 10.1097/FTD.0000000000000941
pii: 00007691-202202000-00009
doi:
Substances chimiques
Anti-Bacterial Agents
0
beta-Lactams
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
86-102Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nguyen DB, Shugart A, Lines C, et al. National Healthcare Safety Network (NHSN) dialysis event surveillance report for 2014. Clin J Am Soc Nephrol. 2017;12:1139–1146.
Pistolesi V, Morabito S, Mario FD, et al. A guide to understanding antimicrobial drug dosing in critically ill patients on renal replacement therapy. Antimicrob Agents Chemother. 2019;63:e00583-19.
Abdul-Aziz MH, Alffenaar JWC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a position paper. Intensive Care Med. 2020;46:1127–1153.
Guilhaumou R, Benaboud S, Bennis Y, et al. Optimization of the treatment with beta-lactam antibiotics in critically ill patients—guidelines from the French Society of Pharmacology and Therapeutics (Société Française de Pharmacologie et Thérapeutique—SFPT) and the French Society of Anaesthesia and Intensive Care Medicine (Société Française d'Anesthésie et Réanimation—SFAR). Crit Care. 2019;23:104.
Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014;14:498–509.
Beumier M, Casu GS, Hites M, et al. β-lactam antibiotic concentrations during continuous renal replacement therapy. Crit Care. 2014;18:R105.
Muller AE, Huttner B, Huttner A. Therapeutic drug monitoring of beta-lactams and other antibiotics in the intensive care unit: which agents, which patients and which infections? Drugs. 2018;78:439–451.
Fissell WH. Antimicrobial dosing in acute renal replacement. Adv Chronic Kidney Dis. 2013;20:85–93.
Wong WT, Choi G, Gomersall CD, et al. To increase or decrease dosage of antimicrobials in septic patients during continuous renal replacement therapy: the eternal doubt. Curr Opin Pharmacol. 2015;24:68–78.
Choi G, Gomersall CD, Tian Q, et al. Principles of antibacterial dosing in continuous renal replacement therapy. Blood Purif. 2010;30:195–212.
Lautrette A, Coudoré F, Souweine B. Principes de l’adaptation posologique des antibiotiques lors d’une épuration extrarénale en réanimation. Réanimation. 2010;19:339–346.
Bourquin V, Ponte B, Saudan P, et al. Adaptation posologique des médicaments couramment utilisés en réanimation lors d’épuration extrarénale continue. Nephrol Ther. 2009;5:533–541.
Levraut J, Orban JC. Pharmacocinétique des antibiotiques et épuration extrarénale continue. Réanimation. 2005;14:519–527.
Schetz M. Drug dosing in continuous renal replacement therapy: general rules. Curr Opin Crit Care. 2007;13:645–651.
KDIGO Clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012;2:1–137.
Clec’h C, Gonzalez F, Lautrette A, et al. Multiple-center evaluation of mortality associated with acute kidney injury in critically ill patients: a competing risks analysis. Crit Care. 2011;15:R128.
Iwagami M, Moriya H, Doi K, et al. Seasonality of acute kidney injury incidence and mortality among hospitalized patients. Nephrol Dial Transpl. 2018;33:1354–1362.
Poukkanen M, Koskenkari J, Vaara ST, et al. Variation in the use of renal replacement therapy in patients with septic shock: a substudy of the prospective multicenter observational FINNAKI study. Crit Care. 2014;18:R26.
Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006;34:1589–1596.
Rhomberg PR, Fritsche TR, Sader HS, et al. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA). Diagn Microbiol Infect Dis. 2006;56:57–62.
Pichot A, Mimoz O, Couet W. Pharmacologie des antibiotiques en réanimation. SFAR, Le Congrès. Les Essentiels. Available at: https://sofia.medicalistes.fr/spip/IMG/pdf/Pharmacologie_des_antibiotiques_en_reanimation.pdf . Published 2013. Accessed November 1 2021.
Gonçalves-Pereira J, Póvoa P. Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care. 2011;15:R206.
Sime FB, Roberts MS, Peake SL, et al. Does beta-lactam pharmacokinetic variability in critically ill patients justify therapeutic drug monitoring? A systematic review. Ann Intensive Care. 2012;2:35.
Osthoff M, Siegemund M, Balestra G, et al. Prolonged administration of β-lactam antibiotics—a comprehensive review and critical appraisal. Swiss Med Wkly. 2016;146:w14368.
Blot SI, Pea F, Lipman J. The effect of pathophysiology on pharmacokinetics in the critically ill patient—concepts appraised by the example of antimicrobial agents. Adv Drug Deliv Rev. 2014;77:3–11.
Bouras M, Floch RL, Asehnoune K, et al. Administration des antibiotiques en réanimation. SFAR, Le Congrès 2017, Conférence d'Actualisation. Available at: https://sfar.org/wp-content/uploads/2017/10/Roquilly-Administration-des-antibiotiques-en-reanimation.pdf . Published 2017. Accessed November 1, 2021.
Bronner S, Levêque D, Jehl F. Les volumes apparents de distribution des antibiotiques: évaluation, intérêt et limites. Antibiotiques. 2006;8:27–38.
Roberts JA, Stove V, Waele JJD, et al. Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study. Int J Antimicrob Agents. 2014;43:423–430.
EMA. Targocid, summary of product characteristics, labelling and package leaflet. Available at: https://www.ema.europa.eu/en/documents/referral/targocid-article-30-referral-annex-iii_en.pdf . Published January 3, 2014. Accessed November 1, 2021.
Velenosi TJ, Urquhart BL. Pharmacokinetic considerations in chronic kidney disease and patients requiring dialysis. Expert Opin Drug Metab Toxicol. 2014;10:1131–1143.
Jamal JA, Udy AA, Lipman J, et al. The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill. Crit Care Med. 2014;42:1640–1650.
Legrand M, Darmon M, Joannidis M, et al. Management of renal replacement therapy in ICU patients: an international survey. Intensive Care Med. 2013;39:101–108.
Golper TA. Drug removal during continuous hemofiltration or hemodialysis. Contrib Nephrol. 1991;93:110–116.
Lorenzen JM, Broll M, Kaever V, et al. Pharmacokinetics of ampicillin/sulbactam in critically ill patients with acute kidney injury undergoing extended dialysis. Clin J Am Soc Nephrol. 2012;7:385–390.
Sinnollareddy MG, Roberts MS, Lipman J, et al. Pharmacokinetics of piperacillin in critically ill patients with acute kidney injury receiving sustained low-efficiency diafiltration. J Antimicrob Chemother. 2018;73:1647–1650.
Richter DC, Frey O, Röhr A, et al. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection. 2019;47:1001–1011.
Donnellan S, Wright DFB, Roberts JA, et al. The pharmacokinetics of meropenem and piperacillin-tazobactam during sustained low efficiency haemodiafiltration (SLED-HDF). Eur J Clin Pharmacol. 2020;76:239–247.
Goh JHF, Lee SY, Ooi ST, et al. Post-hemodialysis dosing of 1 vs. 2 g of ceftazidime in anuric end-stage renal disease patients on low-flux dialysis and its pharmacodynamic implications on clinical use. Hemodial Int. 2016;20:253–260.
Descombes E, Martins F, Hemett OM, et al. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study. BMC Pharmacol Toxicol. 2016;17:4.
Heil EL, Daniels LM, Walko CM, et al. Validation of doripenem dosing in patients with end-stage renal disease receiving hemodialysis. Ann Pharmacother. 2011;45:1455–1456.
Deshpande P, Chen J, Gofran A, et al. Meropenem removal in critically ill patients undergoing sustained low-efficiency dialysis (SLED). Nephrol Dial Transpl. 2010;25:2632–2636.
Shekar K, Fraser JF, Taccone FS, et al. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care. 2014;18:565.
Oliveira MS, Machado AS, Mendes ET, et al. Pharmacokinetic and pharmacodynamic characteristics of vancomycin and meropenem in critically ill patients receiving sustained low-efficiency dialysis. Clin Ther. 2020;42:625–633.
Ďuricová J, Kacířová I, Brozmanová H. Meropenem serum concentrations in intensive care patients a retrospective analysis. Česka Slov Farm. 2020;69:230–236.
Touchard C, Aubry A, Eloy P, et al. Predictors of insufficient peak amikacin concentration in critically ill patients on extracorporeal membrane oxygenation. Crit Care. 2018;22:199.
Marengo LL, Fiolde FSD, Oliveirade SJ, et al. Vancomycin: the need to suit serum concentrations in hemodialysis patients. Braz J Infect Dis. 2010;14:203–208.
Maxson R, Pate J, Starr J. Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients. Ren Fail. 2016;38:1677–1682.
Ghouti-terki L, Chasseuil E, Rabot N, et al. Vancomycin during the last hour of the hemodialysis session: a pharmacokinetic analysis. Nephron. 2017;135:261–267.
Mahmoud LB, Chaabouni Y, Ghozzi H, et al. Optimization of therapeutic drug monitoring of vancomycin in patients with chronic hemodialysis. Clin Nephrol. 2017;88:198–204.
Rider TR, Silinskie KM, Hite MS, et al. Pharmacokinetics of vancomycin in critically ill patients undergoing sustained low-efficiency dialysis. Pharmacotherapy. 2020;40:1036–1041.
Allawati H, Dallas L, Nair S, et al. A pharmacokinetic study comparing the clearance of vancomycin during haemodialysis using medium cut-off membrane (Theranova) and high-flux membranes (Revaclear). Toxins (Basel). 2020;12:317.
Nakamura A, Takasu O, Sakai Y, et al. Development of a teicoplanin loading regimen that rapidly achieves target serum concentrations in critically ill patients with severe infections. J Infect Chemother. 2015;21:449–455.
Fiaccadori E, Maggiore U, Rotelli C, et al. Removal of linezolid by conventional intermittent hemodialysis, sustained low-efficiency dialysis, or continuous venovenous hemofiltration in patients with acute renal failure. Crit Care Med. 2004;32:2437–2442.
Fiaccadori E, Maggiore U, Rotelli C, et al. Does haemodialysis significantly affect serum linezolid concentrations in critically ill patients with renal failure? A pilot investigation. Nephrol Dial Transpl. 2006;21:1402–1406.
Swoboda S, Ober MC, Lichtenstern C, et al. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol. 2010;66:291–298.
Salama NN, Segal JH, Churchwell MD, et al. Intradialytic administration of daptomycin in end stage renal disease patients on hemodialysis. Clin J Am Soc Nephrol. 2009;4:1190–1194.
Salama NN, Segal JH, Churchwell MD, et al. Single-dose daptomycin pharmacokinetics in chronic haemodialysis patients. Nephrol Dial Transpl. 2010;25:1279–1284.
Reiber C, Senn O, Müller D, et al. Therapeutic drug monitoring of daptomycin. Ther Drug Monit. 2015;37:634–640.
Diolez J, Venisse N, Belmouaz S, et al. Pilot pharmacokinetic study of high-dose daptomycin in hemodialysis patients with infected medical devices. Am J Kidney Dis. 2017;70:732–734.
Galar A, Muñoz P, Valerio M, et al. Current use of daptomycin and systematic therapeutic drug monitoring: clinical experience in a tertiary care institution. Int J Antimicrob Agents. 2019;53:40–48.
Schmidt JJ, Strunk AK, David S, et al. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy. J Antimicrob Chemother. 2019;74:997–1002.
Ehrentraut SF, Muenster S, Kreyer S, et al. Extensive therapeutic drug monitoring of colistin in critically ill patients reveals undetected risks. Microorganisms. 2020;8:415.
Vossen MG, Ehmann L, Pferschy S, et al. Elimination of doripenem during dialysis and pharmacokinetic evaluation of posthemodialysis dosing for patients undergoing intermittent renal replacement therapy. Antimicrob Agents Chemother. 2018;62:e02430-17.
Burkhardt O, Hafer C, Langhoff A, et al. Pharmacokinetics of ertapenem in critically ill patients with acute renal failure undergoing extended daily dialysis. Nephrol Dial Transpl. 2009;24:267–271.
Hsaiky LM, Salinitri FD, Wong J, et al. Pharmacokinetics and investigation of optimal dose ertapenem in intermittent hemodialysis patients. Nephrol Dial Transpl. 2018;34:1766–1772.
Mohamed OHK, Wahba IM, Watnick S, et al. Administration of tobramycin in the beginning of the hemodialysis session: a novel intradialytic dosing regimen. Clin J Am Soc Nephrol. 2007;2:694–699.
Guisado-Gil AB, Herrera-Hidalgo L, Santos-Rubio MD, et al. Gentamicin as empirical treatment in hemodialysis patients: safety, pharmacokinetics, and pharmacodynamics. Ther Apher Dial. 2019;23:550–555.
Mueller SC, Majcher-Peszynska J, Hickstein H, et al. Pharmacokinetics of piperacillin-tazobactam in anuric intensive care patients during continuous venovenous hemodialysis. Antimicrob Agents Chemother. 2002;46:1557–1560.
Arzuaga A, Maynar J, Gascón AR, et al. Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration. J Clin Pharmacol. 2005;45:168–176.
Seyler L, Cotton F, Taccone FS, et al. Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care. 2011;15:R137.
Roberts DM, Roberts JA, Roberts MS, et al. Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy. Crit Care Med. 2012;40:1523–1528.
Bauer SR, Salem C, Connor MJ, et al. Pharmacokinetics and pharmacodynamics of piperacillin-tazobactam in 42 patients treated with concomitant CRRT. Clin J Am Soc Nephrol. 2012;7:452–457.
Varghese JM, Jarrett P, Boots RJ, et al. Pharmacokinetics of piperacillin and tazobactam in plasma and subcutaneous interstitial fluid in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2014;43:343–348.
Awissi D, Beauchamp A, Hébert E, et al. Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy. 2015;35:600–607.
Jamal JA, Roberts DM, Udy AA, et al. Pharmacokinetics of piperacillin in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2015;46:39–44.
Roger C, Cotta MO, Muller L, et al. Impact of renal replacement modalities on the clearance of piperacillin-tazobactam administered via continuous infusion in critically ill patients. Int J Antimicrob Agents. 2017;50:227–231.
Kohama H, Ide T, Ikawa K, et al. Pharmacokinetics and outcome of tazobactam/piperacillin in Japanese patients undergoing low-flow continuous renal replacement therapy: dosage considerations. Clin Pharmacol. 2017;9:39–44.
Kühn D, Metz C, Seiler F, et al. Antibiotic therapeutic drug monitoring in intensive care patients treated with different modalities of extracorporeal membrane oxygenation (ECMO) and renal replacement therapy: a prospective, observational single-center study. Crit Care. 2020;24:664.
Scharf C, Paal M, Schroeder I, et al. Therapeutic drug monitoring of meropenem and piperacillin in critical illness—experience and recommendations from one year in routine clinical practice. Antibiotics (Basel). 2020;9:131.
Mariat C, Venet C, Jehl F, et al. Continuous infusion of ceftazidime in critically ill patients undergoing continuous venovenous haemodiafiltration: pharmacokinetic evaluation and dose recommendation. Crit Care. 2006;10:R26.
Philpott CD, Droege CA, Droege ME, et al. Pharmacokinetics and pharmacodynamics of extended-infusion cefepime in critically ill patients receiving continuous renal replacement therapy: a prospective, open-label study. Pharmacotherapy. 2019;39:1066–1076.
Hidaka S, Goto K, Hagiwara S, et al. Doripenem pharmacokinetics in critically ill patients receiving continuous hemodiafiltration (CHDF). Yakuga Zasshi. 2010;130:87–94.
Fish DN, Teitelbaum I, Abraham E. Pharmacokinetics and pharmacodynamics of imipenem during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2005;49:2421–2428.
Afshartous D, Bauer SR, Connor MJ, et al. Pharmacokinetics and pharmacodynamics of imipenem and meropenem in critically ill patients treated with continuous venovenous hemodialysis. Am J Kidney Dis. 2014;63:170–171.
Wen A, Li Z, Yu J, et al. Clinical validation of therapeutic drug monitoring of imipenem in spent effluent in critically ill patients receiving continuous renal replacement therapy: a pilot study. Plos One. 2016;11:e0153927.
Valtonen M, Tiula E, Backman JT, et al. Elimination of meropenem during continuous veno-venous haemofiltration and haemodiafiltration in patients with acute renal failure. J Antimicrob Chemother. 2000;45:701–704.
Giles LJ, Jennings AC, Thomson AH, et al. Pharmacokinetics of meropenem in intensive care unit patients receiving continuous veno-venous hemofiltration or hemodiafiltration. Crit Care Med. 2000;28:632–637.
Ververs TFT, van Dijk A, Vinks SA, et al. Pharmacokinetics and dosing regimen of meropenem in critically ill patients receiving continuous venovenous hemofiltration. Crit Care Med. 2000;28:3412–3416.
Krueger WA, Neeser G, Schuster H, et al. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration. Chemotherapy. 2003;49:280–286.
Robatel C, Decosterd LA, Biollaz J, et al. Pharmacokinetics and dosage adaptation of meropenem during continuous venovenous hemodiafiltration in critically ill patients. J Clin Pharmacol. 2003;43:1329–1340.
Isla A, Maynar J, Sánchez-Izquierdo JÁ, et al. Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients. J Clin Pharmacol. 2005;45:1294–1304.
Langgartner J, Vasold A, Glück T, et al. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy. Intensive Care Med. 2008;34:1091–1096.
Varghese JM, Jarrett P, Wallis SC, et al. Are interstitial fluid concentrations of meropenem equivalent to plasma concentrations in critically ill patients receiving continuous renal replacement therapy? J Antimicrob Chemother. 2015;70:528–533.
Jamal JA, Mat-Nor MB, Mohamad-Nor FS, et al. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration. Int J Antimicrob Agents. 2015;45:41–45.
Nowak-Kózka I, Polok KJ, Górka J, et al. Concentration of meropenem in patients with sepsis and acute kidney injury before and after initiation of continuous renal replacement therapy: a prospective observational trial. Pharmacol Rep. 2020;72:147–155.
Taccone FS, de Backer D, Laterre PF, et al. Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy. Int J Antimicrob Agents. 2011;37:531–535.
D'Arcy DM, Casey E, Gowing CM, et al. An open prospective study of amikacin pharmacokinetics in critically ill patients during treatment with continuous venovenous haemodiafiltration. BMC Pharmacol Toxicol. 2012;13:14.
Petejova N, Zahalkova J, Duricova J, et al. Gentamicin pharmacokinetics during continuous venovenous hemofiltration in critically ill septic patients. J Chemother. 2013;24:107–112.
Ruiz-Ramos J, Gimeno R, Pérez F, et al. Pharmacokinetics of amikacin in critical care patients on extracorporeal device. ASAIO J. 2018;64:686–688.
Syka M, Markantonis SL, Mathas C, et al. A pilot study of netilmicin pharmacokinetics during continuous venovenous hemodiafiltration. J Clin Pharmacol. 2005;45:477–481.
Covajes C, Scolletta S, Penaccini L, et al. Continuous infusion of vancomycin in septic patients receiving continuous renal replacement therapy. Int J Antimicrob Agents. 2013;41:261–266.
Udy AA, Covajes C, Taccone FS, et al. Can population pharmacokinetic modelling guide vancomycin dosing during continuous renal replacement therapy in critically ill patients? Int J Antimicrob Agents. 2013;41:564–568.
DelDot ME, Lipman J, Tett SE. Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol. 2004;58:259–268.
Beumier M, Roberts JA, Kabtouri H, et al. A new regimen for continuous infusion of vancomycin during continuous renal replacement therapy. J Antimicrob Chemother. 2013;68:2859–2865.
Chaijamorn W, Jitsurong A, Wiwattanawongsa K, et al. Vancomycin clearance during continuous venovenous haemofiltration in critically ill patients. Int J Antimicrob Agents. 2011;38:152–156.
Omrani AS, Mously A, Cabaluna MP, et al. Vancomycin therapy in critically ill patients on continuous renal replacement therapy; are we doing enough? Saudi Pharm J. 2015;23:327–329.
Marella P, Roberts J, Hay K, et al. Effectiveness of vancomycin dosing guided by therapeutic drug monitoring in adult patients receiving extracorporeal membrane oxygenation. Antimicrob Agents Chemother. 2020:64:e01179-20.
Akers KS, Cota JM, Chung KK, et al. Serum vancomycin levels resulting from continuous or intermittent infusion in critically ill burn patients with or without continuous renal replacement therapy. J Burn Care Res. 2012;33:e254–e262.
Oda K, Jono H, Kamohara H, et al. Development of vancomycin dose individualization strategy by Bayesian prediction in patients receiving continuous renal replacement therapy. Pharmaceut Res. 2020;37:108.
Bakke V, Sporsem H, der Lipper EV, et al. Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study. Acta Anaesthesiol Scand. 2017;61:627–635.
Yang CJ, Wu CW, Wu CC. Effect of extracorporeal membrane oxygenation on the new vancomycin dosing regimen in critically ill patients receiving continuous venovenous hemofiltration. Ther Drug Monit. 2018;40:310–314.
Petejova N, Martinek A, Zahalkova J, et al. Vancomycin pharmacokinetics during high-volume continuous venovenous hemofiltration in critically ill septic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2014;158:65–72.
Wilson FP, Berns JS. Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD). Clin Nephrol. 2012;77:329–331.
Lim SK, Lee SA, Kim C, et al. High variability of teicoplanin concentration in patients with continuous venovenous hemodiafiltration. Hemodial Int. 2019;23:69–76.
Bellmann R, Falkensammer G, Seger C, et al. Teicoplanin pharmacokinetics in critically ill patients on continuous veno-venous hemofiltration. Int J Clin Pharm Ther. 2010;48:243–249.
Zoller M, Maier B, Hornuss C, et al. Variability of linezolid concentrations after standard dosing in critically ill patients: a prospective observational study. Crit Care. 2014;18:R148.
Corcione S, D'Avolio A, Allegra S, et al. Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. Int J Antimicrob Agents. 2017;49:784–785.
Barrasa H, Soraluce A, Isla A, et al. Pharmacokinetics of linezolid in critically ill patients on continuous renal replacement therapy: influence of residual renal function on PK/PD target attainment. J Crit Care. 2019;50:69–76.
Wenisch JM, Meyer B, Fuhrmann V, et al. Multiple-dose pharmacokinetics of daptomycin during continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2012;67:977–983.
Preiswerk B, Rudiger A, Fehr J, et al. Experience with daptomycin daily dosing in ICU patients undergoing continuous renal replacement therapy. Infection. 2013;41:553–557.
Shotwell MS, Madonia PN, Connor MJ, et al. Ciprofloxacin pharmacokinetics in critically ill patients receiving concomitant continuous venovenous hemodialysis. Am J Kidney Dis. 2015;66:173–175.
Spooner AM, Deegan C, D'Arcy DM, et al. An evaluation of ciprofloxacin pharmacokinetics in critically ill patients undergoing continuous veno-venous haemodiafiltration. BMC Clin Pharmacol. 2011;11:11.
Wallis SC, Mullany DV, Lipman J, et al. Pharmacokinetics of ciprofloxacin in ICU patients on continuous veno-venous haemodiafiltration. Intensive Care Med. 2001;27:665–672.
Onichimowski D, Wolska J, Ziółkowski H, et al. Pharmacokinetics of ciprofloxacin during continuous renal replacement therapy in intensive care patients—new assessment. Anaesthesiol Intensiv Ther. 2020;52:267–273.
Traunmüller F, Thalhammer-Scherrer R, Locker GJ, et al. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother. 2001;47:229–231.
Fuhrmann V, Schenk P, Jaeger W, et al. Pharmacokinetics of moxifloxacin in patients undergoing continuous venovenous haemodiafiltration. J Antimicrob Chemother. 2004;54:780–784.
Broeker A, Wicha SG, Dorn C, et al. Tigecycline in critically ill patients on continuous renal replacement therapy: a population pharmacokinetic study. Crit Care. 2018;22:341.
Hong-huan Z, Tang WJ, Yuan-xia Y, Cen ZR, Li-qing W. PK/PD study of tigecycline in severely infected patients with continuous renal replacement therapy. Int J Clin Pharmacol Ther. 2020;58:531–538.
Meyer B, el Gendy SA, Karth GD, et al. How to calculate clearance of highly protein-bound drugs during continuous venovenous hemofiltration demonstrated with flucloxacillin. Kidney Blood Press Res. 2003;26:135–140.
Traunmüller F, Schenk P, Mittermeyer C, et al. Clearance of ceftazidime during continuous venovenous haemofiltration in critically ill patients. J Antimicrob Chemother. 2002;49:129–134.
Malone RS, Fish DN, Abraham E, et al. Pharmacokinetics of cefepime during continuous renal replacement therapy in critically ill patients. Antimicrob Agents Chemother. 2001;45:3148–3155.
Wilson FP, Bachhuber MA, Caroff D, et al. Low cefepime concentrations during high blood and dialysate flow continuous venovenous hemodialysis. Antimicrob Agents Chermother. 2012;56:2178–2180.
Gao C, Tong J, Yu K, et al. Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration. Eur J Clin Pharmacol. 2016;72:823–830.
Banyai M, Thalhammer F, Menyawi IE, et al. Pharmacokinetics of cefpirome during continuous venovenous hemofiltration: rationale for an 8-hour dosing interval. Clin Pharmacol Ther. 2000;67:368–372.
Bilgrami I, Roberts JA, Wallis SC, et al. Meropenem dosing in critically ill patients with sepsis receiving high-volume continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2010;54:2974–2978.
Akers KS, Cota JM, Frei CR, et al. Once-daily amikacin dosing in burn patients treated with continuous venovenous hemofiltration. Antimicrob Agents Chemother. 2011;55:4639–4642.
Tian Q, Gomersall CD, Ip M, et al. Adsorption of amikacin, a significant mechanism of elimination by hemofiltration. Antimicrob Agents Chemother. 2008;52:1009–1013.
Lam SW, Bauer SR. Amikacin pharmacokinetics during continuous veno-venous hemodialysis. Infect Dis Ther. 2013;2:217–226.
Baud FJ, Houzé P, Carli P, et al. Alteration of the pharmacokinetics of aminoglycosides by adsorption in a filter during continuous renal replacement therapy. An in vitro assessment. Therapie. 2020;76:415–424.
Pea F, Viale P, Pavan F, et al. Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy. Clin Pharmacokinet. 2007;46:997–1038.
van der Werf TS, Mulder POM, Zijlstra JG, et al. Pharmacokinetics of piperacillin and tazobactam in critically ill patients with renal failure, treated with continuous veno-venous hemofiltration (CVVH). Intensive Care Med. 1997;23:873–877.
Tegeder I, Schmidtko A, Bräutigam L, et al. Tissue distribution of imipenem in critically ill patients. Clin Pharmacol Ther. 2002;71:325–333.
Hites M, Taccone FS, Wolff F, et al. Case-control study of drug monitoring of β-lactams in obese critically ill patients. Antimicrob Agents Chemother. 2013;57:708–715.
Roberts JA, Paul SK, Akova M, et al. DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis. 2014;58:1072–1083.
Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(suppl 1):S35–S39.
Launay-Vacher V, Izzedine H, Mercadal L, et al. Clinical review: use of vancomycin in haemodialysis patients. Crit Care. 2002;6:313.
Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin Pharmacokinet. 2001;40:169–187.
Czock D, Hüsig-Linde C, Langhoff A, et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol. 2006;1:1263–1268.
Dvorchik B, Damphousse D. Single-dose pharmacokinetics of daptomycin in young and geriatric volunteers. J Clin Pharmacol. 2004;44:612–620.
Corti N, Rudiger A, Chiesa A, et al. Pharmacokinetics of daily daptomycin in critically ill patients undergoing continuous renal replacement therapy. Chemotherapy. 2013;59:143–151.
Meagher AK, Ambrose PG, Grasela TH, et al. The pharmacokinetic and pharmacodynamic profile of tigecycline. Clin Infect Dis. 2005;41(suppl 5):S333–S340.
Bergen PJ, Li J, Nation RL. Dosing of colistin—back to basic PK/PD. Curr Opin Pharmacol. 2011;11:464–469.
Jacobs M, Grégoire N, Mégarbane B, et al. Population pharmacokinetics of colistin methanesulfonate and colistin in critically ill patients with acute renal failure requiring intermittent hemodialysis. Antimicrob Agents Chemother. 2016;60:1788–1793.
Mohamed AF, Karaiskos I, Plachouras D, et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother. 2012;56:4241–4249.
Cheah SE, Wang J, Nguyen VTT, et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response in lung infection. J Antimicrob Chemother. 2015;70:3291–3297.
Garonzik SM, Li J, Thamlikitkul V, et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother. 2011;55:3284–3294.
Nation RL, Garonzik SM, Thamlikitkul V, et al. Dosing guidance for intravenous colistin in critically-ill patients. Clin Infect Dis. 2017;64:565–571.
Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother. 2012;67:2459–2462.
Honore P, Jacobs R, Lochy S, et al. Acute respiratory muscle weakness and apnea in a critically ill patient induced by colistin neurotoxicity: key potential role of hemoadsorption elimination during continuous venovenous hemofiltration. Int J Nephrol Renovasc Dis. 2013;6:107–111.
Leporati M, Bua RO, Mariano F, et al. Determination by LC–MS/MS of colistins A and B in plasma and ultrafiltrate from critically ill patients undergoing continuous venovenous hemodiafiltration. Ther Drug Monit. 2014;36:182–191.
Mariano F, Leporati M, Carignano P, et al. Efficient removal of colistin A and B in critically ill patients undergoing CVVHDF and sorbent technologies. J Nephrol. 2015;28:623–631.
Jitmuang A, Nation RL, Koomanachai P, et al. Extracorporeal clearance of colistin methanesulphonate and formed colistin in end-stage renal disease patients receiving intermittent haemodialysis: implications for dosing. J Antimicrob Chemother. 2015;70:1804–1811.
Karaiskos I, Friberg LE, Galani L, et al. Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration. Int J Antimicrob Agents. 2016;48:337–341.
Kashuba ADM, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999;43:623–629.
Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2020;77:835–864.
Neely MN, Kato L, Youn G, et al. Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing. Antimicrob Agents Chemother. 2018;62:e02042-17.
Barras MA, Serisier D, Hennig S, et al. Bayesian estimation of tobramycin exposure in patients with cystic fibrosis. Antimicrob Agents Chemother. 2016;60:6698–6702.
Wong G, Briscoe S, Adnan S, et al. Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother. 2013;57:6165–6170.
Mouton JW, Muller AE, Canton R, et al. MIC-based dose adjustment: facts and fables. J Antimicrob Chemother. 2017;73:564–568.
Brater D. Drug dosing in patients with impaired renal function. Clin Pharmacol Ther. 2009;86:483–489.
Wicha SG, Märtson A, Nielsen EI, et al. From therapeutic drug monitoring to model-informed precision dosing for antibiotics. Clin Pharmacol Ther. 2021;109:928–941.
Duszynska W, Taccone FS, Hurkacz M, et al. Therapeutic drug monitoring of amikacin in septic patients. Crit Care. 2013;17:R165.
Ruiz-Ramos J, Villarreal E, Gordon M, et al. Implication of haemodiafiltration flow rate on amikacin pharmacokinetic parameters in critically ill patients. Blood Purif. 2018;45:88–94.
Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis. 1987;155:93–99.
Zelenitsky SA, Harding GKM, Sun S, et al. Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. J Antimicrob Chemother. 2003;52:668–674.
O'Shea S, Duffull S, Johnson DW. Aminoglycosides in hemodialysis patients: is the current practice of post dialysis dosing appropriate? Semin Dial. 2009;22:225–230.
Dang L, Duffull S. Development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis. J Clin Pharmacol. 2006;46:662–673.
Sowinski KM, Magner SJ, Lucksiri A, et al. Influence of hemodialysis on gentamicin pharmacokinetics, removal during hemodialysis, and recommended dosing. Clin J Am Soc Nephrol. 2008;3:355–361.
Teigen MMB, Duffull S, Dang L, et al. Dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis. J Clin Pharmacol. 2006;46:1259–1267.
Veinstein A, Venisse N, Badin J, et al. Gentamicin in hemodialyzed critical care patients: early dialysis after administration of a high dose should be considered. Antimicrob Agents Chemother. 2013;57:977–982.
Fiore M, Peluso L, Taccone FS, et al. The impact of continuous renal replacement therapy on antibiotic pharmacokinetics in critically ill patients. Expert Opin Drug Metab Toxicol. 2021;17:543–554.
Bartal C, Danon A, Schlaeffer F, et al. Pharmacokinetic dosing of aminoglycosides: a controlled trial. Am J Med. 2003;114:194–198.
Begg E, Barclay M, Duffull S. A suggested approach to once-daily aminoglycoside dosing. Br J Clin Pharmacol. 1995;39:605–609.
Delattre IK, Musuamba FT, Nyberg J, et al. Population pharmacokinetic modeling and optimal sampling strategy for Bayesian estimation of amikacin exposure in critically ill septic patients. Ther Drug Monit.. 2010;32:749–756.
van Lent-Evers NA, Mathôt RA, Geus WP, et al. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit. 1999;21:63–73.
McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents. 2008;31:345–351.
Tam VH, McKinnon PS, Akins RL, et al. Pharmacodynamics of cefepime in patients with Gram-negative infections. J Antimicrob Chemother. 2002;50:425–428.
Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007;51:1725–1730.
Aitken SL, Altshuler J, Guervil DJ, et al. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015;45:541–544.
Payne LE, Gagnon DJ, Riker RR, et al. Cefepime-induced neurotoxicity: a systematic review. Crit Care. 2017;21:276.
Beumier M, Casu GS, Hites M, et al. Elevated β-lactam concentrations associated with neurological deterioration in ICU septic patients. Minerva Anestesiol. 2014;81:497–506.
Imani S, Buscher H, Marriott D, et al. Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships. J Antimicrob Chemother. 2017;72:2891–2897.
Huwyler T, Lenggenhager L, Abbas M, et al. Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study. Clin Microbiol Infect. 2017;23:454–459.
Lamoth F, Buclin T, Pascual A, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54:4360–4367.
Quinton MC, Bodeau S, Kontar L, et al. Neurotoxic concentration of piperacillin during continuous infusion in critically Ill patients. Antimicrob Agents Chemother. 2017;61:e00654-17.
Roberts JA, Ulldemolins M, Roberts MS, et al. Therapeutic drug monitoring of β-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents. 2010;36:332–339.
Waele JJD, Carrette S, Carlier M, et al. Therapeutic drug monitoring-based dose optimisation of piperacillin and meropenem: a randomised controlled trial. Intensive Care Med. 2014;40:380–387.
Taccone FS, Cotton F, Roisin S, et al. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother. 2012;56:2129–2131.
Flannery AH, Bissell BD, Bastin MT, et al. Continuous versus intermittent infusion of vancomycin and the risk of acute kidney injury in critically ill adults: a systematic review and meta-analysis. Crit Care Med. 2020;48:912–918.
Rodvold KA. Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside. Pharmacotherapy. 2001;21:319S–330S.
Pea F, Cojutti PG, Baraldo M. A 10-year experience of therapeutic drug monitoring (TDM) of linezolid in a hospital-wide population of patients receiving conventional dosing: is there enough evidence for suggesting TDM in the majority of patients? Basic Clin Pharmacol Toxicol. 2017;121:303–308.
Rubino CM, Bhavnani SM, Forrest A, et al. Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired Pneumonia. Antimicrob Agents Chemother. 2012;56:130–136.
Meagher AK, Passarell JA, Cirincione BB, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother. 2007;51:1939–1945.
Passarell JA, Meagher AK, Liolios K, et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother. 2008;52:204–210.
Dudhani RV, Turnidge JD, Coulthard K, et al. Elucidation of the pharmacokinetic/pharmacodynamic determinant of colistin activity against Pseudomonas aeruginosa in murine thigh and lung infection models. Antimicrob Agents Chemother. 2010;54:1117–1124.
Dudhani RV, Turnidge JD, Nation RL, et al. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J Antimicrob Chemother. 2010;65:1984–1990.
Horcajada JP, Sorlí L, Luque S, et al. Validation of a colistin plasma concentration breakpoint as a predictor of nephrotoxicity in patients treated with colistin methanesulfonate. Int J Antimicrob Agents. 2016;48:725–727.
Sorlí L, Luque S, Grau S, et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis. 2013;13:380.
Forrest A, Garonzik SM, Thamlikitkul V, et al. Pharmacokinetic/toxicodynamic analysis of colistin-associated acute kidney injury in critically ill patients. Antimicrob Agents Chemother. 2017;61:e01367-17.
Phe K, Johnson ML, Palmer HR, et al. Validation of a model to predict the risk of nephrotoxicity in patients receiving colistin. Antimicrob Agents Chemother. 2014;58:6946–6948.
Pogue JM, Lee J, Marchaim D, et al. Incidence of and risk factors for colistin-associated nephrotoxicity in a large academic health system. Clin Infect Dis. 2011;53:879–884.
Rattanaumpawan P, Ungprasert P, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. J Infect. 2011;62:187–190.
Tsuji BT, Pogue JM, Zavascki AP, et al. International consensus guidelines for the optimal use of the polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;39:10–39.
Li A, Gomersall CD, Choi G, et al. A systematic review of antibiotic dosing regimens for septic patients receiving continuous renal replacement therapy: do current studies supply sufficient data? J Antimicrob Chemother. 2009;64:929–937.
Vaara S, Pettila V, Kaukonen K.-M. Quality of pharmacokinetic studies in critically ill patients receiving continuous renal replacement therapy. Acta Anaesthesiol Scand. 2012;56:147–157.